Vulvovaginal atrophy: modern approaches to diagnostics and management
DOI:
https://doi.org/10.14739/2310-1210.2024.6.311942Keywords:
vulvovaginal atrophy, genitourinary menopause syndrome, menopause, postmenopause, hypoestrogenism, diagnosis, treatment, photodynamic therapyAbstract
The aim of the review is to analyze the latest data on the current state of diagnosis and management of a common benign vulvar and vaginal disease in postmenopausal women – atrophic vulvovaginitis.
The paper presents an analysis of national and foreign scientific publications on the diagnosis and management of vulvovaginal atrophy and also focuses on the modern nomenclature and terminology of this pathology. Vulvovaginal atrophy is a common and progressive condition affecting on average more than 50 % of postmenopausal women, and its development and severity depend mainly on the duration of hypoestrogenism. Such a hormonal imbalance with a gradually increasing estrogen deficiency leads to atrophic changes in the tissues of the female genital organs and thinning of the vaginal epithelium. Degenerative alterations are accompanied by inflammatory phenomena and disturbances in the vaginal microflora. Atrophic lesions in the genitourinary system induce urinary incontinence aggravation, dysuria, increased micturition frequency, and recurrent urinary tract infections.
Vulvovaginal atrophy is diagnosed based on appropriate clinical assessments as well as with the involvement of validated questionnaires. Differential diagnosis of the vulvovaginal atrophy should include all pathological conditions imitating the clinical symptoms and signs.
Experts of the International Society for the Study of Women’s Sexual Health and the North American Society of Menopause have proposed a new nomenclature, namely, the terms “vulvovaginal atrophy” and “atrophic vaginitis” have been supplanted by “genitourinary menopausal syndrome”.
First-line therapy for mild symptoms is non-hormonal vulvar and vaginal lubricants, vaginal moisturizers used on a regular basis. Hormonal therapy (both transdermal and oral) remains the most effective choice for the treatment of clinical manifestations, but contraindications to its use should be considered. In women with contraindications to systemic hormonal therapy, it is possible to prescribe estrogens in the form of vaginal suppositories or vaginal cream. 5-Aminolevulinic acid photodynamic therapy can be one of the promising methods in the treatment of this women’s clinical group.
Given the serious consequences of vulvovaginal atrophy for the patients’ health and quality of life, timely diagnosis of the disease in accordance with its specificity and possible complications is of primary importance for the successful treatment and management of this pathology.
Conclusions. Vulvovaginal atrophy has been shown to be a common disease, especially among women in the postmenopausal period, based on the analysis of national and foreign scientific publications. The pathogenesis of vulvovaginal atrophy is associated with hypoestrogeny which results in structural and functional abnormalities of the genital organs such as mucus thinning, loss of elasticity, changes in microbiota and increased pH. Given the new nomenclature and terminology, it is appropriate to use the term “genitourinary menopausal syndrome” (GMS or GUMS) in lieu of “vulvovaginal atrophy”.
References
La Rosa VL, Ciebiera M, Lin LT, Fan S, Butticè S, Sathyapalan T, Jet al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Prz Menopauzalny. 2019;18(2):116-22. doi: https://doi.org/10.5114/pm.2019.86836
Cox S, Nasseri R, Rubin RS, Santiago-Lastra Y. Genitourinary Syndrome of Menopause. Med Clin North Am. 2023;107(2):357-69. doi: https://doi.org/10.1016/j.mcna.2022.10.017
Shim S, Park KM, Chung YJ, Kim MR. Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements. J Menopausal Med. 2021;27(1):1-7. doi: https://doi.org/10.6118/jmm.20034
Ilhan G, Aslan MM, Cevrioglu AS, Yıldırım M, Erkorkmaz U. Clinical Efficacy of Hormonal and Nonhormonal Agents in the Treatment of Vulvovaginal Atrophy. J Menopausal Med. 2021;27(1):15-23. doi: https://doi.org/10.6118/jmm.20026
Popkov О.V. [Benefits of topical estrogen in the treatment of urogenital menopause syndrome]. Ukrainian medical journal. 2021;0(6):2-6. Ukrainian. doi: https://doi.org/10.32471/umj.1680-3051.146.223310
Costa AP, Sarmento AC, Vieira-Baptista P, Eleutério J Jr, Cobucci RN, Gonçalves AK. Hormonal Approach for Postmenopausal Vulvovaginal Atrophy. Front Reprod Health. 2021;3:783247. doi: https://doi.org/10.3389/frph.2021.783247
Pérez-López FR, Vieira-Baptista P, Phillips N, Cohen-Sacher B, Fialho SC, Stockdale CK. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecol Endocrinol. 2021;37(8):740-5. doi: https://doi.org/10.1080/09513590.2021.1931100
Ojha N, Bista KD, Bajracharya S, Katuwal N. Genitourinary Syndrome of Menopause among Postmenopausal Women in a Tertiary Care Centre: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2022;60(246):126-31. doi: https://doi.org/10.31729/jnma.7237
Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36-44. doi: https://doi.org/10.3109/13697137.2011.647840
Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-9. doi: https://doi.org/10.1111/jsm.12190
Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. J Sex Med. 2017;14(3):413-24. doi: https://doi.org/10.1016/j.jsxm.2017.01.010
Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704-11. doi: 1 https://doi.org/0.1016/j.ajog.2016.07.045
Lev-Sagie A. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations. Clin Obstet Gynecol. 2015;58(3):476-91. doi: https://doi.org/10.1097/GRF.0000000000000126
Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Pecchio S, Nappi RE. Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?. Clin Breast Cancer. 2015;15(6):413-20. doi: https://doi.org/10.1016/j.clbc.2015.06.005
Nappi RE, Biglia N, Cagnacci A, Di Carlo C, Luisi S, Paoletti AM. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol. 2016;32(8):602-6. doi: https://doi.org/10.1080/09513590.2016.1183627
The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. doi: https://doi.org/10.1097/GME.0000000000001609
North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3 Pt 1):355-71. doi: https://doi.org/10.1097/gme.0b013e31805170eb
Stika CS. Atrophic vaginitis. Dermatol Ther. 2010;23(5):514-22. doi: https://doi.org/10.1111/j.1529-8019.2010.01354.x
Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol. 2004;190(5):1272-7. doi: https://doi.org/10.1016/j.ajog.2003.12.015
Stabile G, Topouzova GA, De Seta F. The role of microbiota in the management of genitourinary syndrome of menopause. Climacteric. 2023;26(4):353-60. doi: https://doi.org/10.1080/13697137.2023.2223923
Micks E, Reed SD, Mitchell C. The Postmenopausal Vaginal Microbiome and Genitourinary Syndrome of Menopause. Clin Obstet Gynecol. 2024;67(1):79-88. doi: https://doi.org/10.1097/GRF.0000000000000832
Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med. 2009;6(3):603-619. doi: https://doi.org/10.1111/j.1743-6109.2008.01198.x
Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-22. doi: https://doi.org/10.3109/13697137.2010.522875
Palacios S, Combalia J, Emsellem C, Gaslain Y, Khorsandi D. Therapies for the management of genitourinary syndrome of menopause. Post Reprod Health. 2020;26(1):32-42. doi: https://doi.org/10.1177/2053369119866341
Traish AM, Vignozzi L, Simon JA, Goldstein I, Kim NN. Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sex Med Rev. 2018;6(4):558-71. doi: https://doi.org/10.1016/j.sxmr.2018.03.005
Mension E, Alonso I, Tortajada M, Matas I, Gómez S, Ribera L, Ros C, Anglès-Acedo S, Castelo-Branco C. Genitourinary Syndrome of Menopause Assessment Tools. J Midlife Health. 2021;12(2):99-102. doi: https://doi.org/10.4103/jmh.jmh_93_21
Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208. doi: https://doi.org/10.1080/009262300278597
Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J. 2015;26(1):15-28. doi: https://doi.org/10.1007/s00192-014-2464-0
McEndree B. Clinical application of the vaginal maturation index. Nurse Pract. 1999;24(9):48-56.
O'Connell TX, Nathan LS, Satmary WA, Goldstein AT. Non-neoplastic epithelial disorders of the vulva. Am Fam Physician. 2008;77(3):321-6.
Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014;21(5):450-8. doi: https://doi.org/10.1097/GME.0b013e3182a4690b
Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321-30. doi: https://doi.org/10.1097/GME.0000000000001236
Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Climacteric. 2014;17(5):557-63. doi: https://doi.org/10.3109/13697137.2014.946279
Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas. 2016;83:40-4. doi: https://doi.org/10.1016/j.maturitas.2015.09.001
Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167-73. doi: https://doi.org/10.1080/13697137.2017.1421921
Farahat RA, Salamah HM, Mahmoud A, Hamouda E, Hashemy M, Hamouda H, et al. The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis. BMC Womens Health. 2023;23(1):494. doi: https://doi.org/10.1186/s12905-023-02645-0
Tersigni C, Di Simone N, Tempestilli E, Cianfrini F, Russo R, Moruzzi MC, et al. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women. J Obstet Gynaecol. 2015;35(8):835-8. doi: https://doi.org/10.3109/01443615.2015.1014326
Hocké C, Diaz M, Bernard V, Frantz S, Lambert M, Mathieu C, et al. Syndrome génito-urinaire de la ménopause (SGUM). RPC les femmes ménopausées du CNGOF et du GEMVi [Genitourinary menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol. 2021;49(5):394-13. French. doi: https://doi.org/10.1016/j.gofs.2021.03.025
Reed BD, Harlow SD, Legocki LJ, Helmuth ME, Haefner HK, Gillespie BW, et al. Oral contraceptive use and risk of vulvodynia: a population-based longitudinal study. BJOG. 2013;120(13):1678-84. doi: https://doi.org/10.1111/1471-0528.12407
Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2015;18 Suppl 1:18-22. doi: https://doi.org/10.3109/13697137.2015.1078206
Sarmento AC, Kamilos MF, Costa AP, Vieira-Baptista P, Eleutério J Jr, Gonçalves AK. Use of Moisturizers and Lubricants for Vulvovaginal Atrophy. Front Reprod Health. 2021;3:781353. doi: https://doi.org/10.3389/frph.2021.781353
Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women. Menopause. 2018;25(12):1418-23. doi: https://doi.org/10.1097/GME.0000000000001148
Ministry of Health of Ukraine. [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Menopausal disorders and other disorders in the perimenopausal period"]. Order dated 2022 Jun 17, No. 1039. [Internet]. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/37474-dn_1039_17_06_2022_dod.pdf
Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause. 2014;21(3):309-19. doi: https://doi.org/10.1097/GME.0b013e31829755ed
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-53. doi: https://doi.org/10.1097/GME.0000000000000921
Ministry of Health of Ukraine. [Evidence-Based Clinical Guidelines Menopausal Disorders and Other Perimenopausal Disorders] [Internet]. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/2022_01_13_kn_menopauz_rozlady.pdf
Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?. Climacteric. 2016;19(2):151-61. doi: https://doi.org/10.3109/13697137.2015.1124259
Mills BB. Vaginitis: Beyond the Basics. Obstet Gynecol Clin North Am. 2017;44(2):159-77. doi: https://doi.org/10.1016/j.ogc.2017.02.010
Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95. doi: https://doi.org/10.1097/gme.0b013e31824d8f40
Heller DS, Weiss G, Bittman S, Goldsmith L. Does a diagnosis of atrophic vaginitis on Papanicolaou test signify the presence of inflammation?. Menopause. 2015;22(8):814-5. doi: https://doi.org/10.1097/GME.0000000000000393
Nappi RE, Kotek M, Breštánský A, Giordan N, Beriotto I, Tramentozzi E. Treatment of vulvo-vaginal atrophy with hyaluronate-based gel: a randomized controlled study. Minerva Obstet Gynecol. 2022;74(6):480-8. doi: https://doi.org/10.23736/S2724-606X.21.04841-7
Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17(1):3-9. doi: https://doi.org/10.3109/13697137.2013.871696
Kovacevic N, Cilensek I, Merlo S, Segedin B. Modern approach to the management of genitourinary syndrome in women with gynecological malignancies. Radiol Oncol. 2023;57(3):292-8. doi: https://doi.org/10.2478/raon-2023-0038
Rioux JE, Devlin MC, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2018;25(11):1208-13. doi: https://doi.org/10.1097/GME.0000000000001220
Motlani G, Motlani V, Acharya N, Dave A, Pamnani S, Somyani D, et al. Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift. Cureus. 2023;15(11):e49079. doi: https://doi.org/10.7759/cureus.49079
Archer DF. Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy. Menopause. 2020;27(8):846-7. doi: https://doi.org/10.1097/GME.0000000000001600
Leibaschoff G, Izasa PG, Cardona JL, Miklos JR, Moore RD. Transcutaneous Temperature Controlled Radiofrequency (TTCRF) for the Treatment of Menopausal Vaginal/Genitourinary Symptoms. Surg Technol Int. 2016;29:149-59.
Lee A, Kim TH, Lee HH, Kim YS, Enkhbold T, Lee B, et al. Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials. J Menopausal Med. 2018;24(1):1-10. doi: https://doi.org/10.6118/jmm.2018.24.1.1
Kwon TR, Kim JH, Seok J, Kim JM, Bak DH, Choi MJ, et al. Fractional CO2 laser treatment for vaginal laxity: A preclinical study. Lasers Surg Med. 2018 Sep;50(9):940-947. doi: https://doi.org/10.1002/lsm.22940
Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Falagas ME, Salvatore S, et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results. Menopause. 2019;26(3):248-55. doi: https://doi.org/10.1097/GME.0000000000001206
Fan W, Tang J, Tang S, Lin Z, Li M, Zhang Z, Wu D. Bibliometric analysis of photodynamic therapy and immune response from 1989-2023. Front Pharmacol. 2024 Jan 15;15:1299253. doi: https://doi.org/10.3389/fphar.2024.1299253
Sun J, Zhao H, Fu L, Cui J, Yang Y. Global Trends and Research Progress of Photodynamic Therapy in Skin Cancer: A Bibliometric Analysis and Literature Review. Clin Cosmet Investig Dermatol. 2023;16:479-98. doi: https://doi.org/10.2147/CCID.S401206
Huang F, Fu Q, Tang L, Zhao M, Huang M, Zhou X. Trends in photodynamic therapy for dermatology in recent 20 years: A scientometric review based on CiteSpace. J Cosmet Dermatol. 2024;23(2):391-402. doi: https://doi.org/10.1111/jocd.16033
Qiu L, Li J, Chen F, Wang Y, Wang Y, Wang X, et al. Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022). Photodiagnosis Photodyn Ther. 2022;39:102993. doi: https://doi.org/10.1016/j.pdpdt.2022.102993
Lan T, Zou Y, Hamblin MR, Yin R. 5-Aminolevulinic acid photodynamic therapy in refractory vulvar lichen sclerosus et atrophicus: Series of ten cases. Photodiagnosis Photodyn Ther. 2018;21:234-8. doi: https://doi.org/10.1016/j.pdpdt.2017.12.003
Ou S, Wang H, Liu W, Zhu H, Zhang W, Li H, et al. Combination of high-frequency electrocautery therapy and ALA-PDT in hyperkeratotic vulvar lichen sclerosus: Series of seven cases. Photodiagnosis Photodyn Ther. 2024;45:103924. doi: https://doi.org/10.1016/j.pdpdt.2023.103924
Singh N, Mishra N, Ghatage P. Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review. Cureus. 2021;13(2):e13527. doi: https://doi.org/10.7759/cureus.13527
Corazza M, Schettini N, Zedde P, Borghi A. Vulvar Lichen Sclerosus from Pathophysiology to Therapeutic Approaches: Evidence and Prospects. Biomedicines. 2021;9(8):950. doi: https://doi.org/10.3390/biomedicines9080950
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
